Regeneron

Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established treatment, according to a Benzinga report. The claim, if supported by trial data, would position the biotech as a credible challenger in the competitive market for retinal disease therapies, where Regeneron's medicine has long been a dominant option.

Regeneron is being highlighted for its science-driven approach to corporate communications, distinguishing its brand strategy within the pharmaceutical industry. A report examines how the company leans on scientific credibility rather than traditional marketing to shape its public image, positioning it as a notable example among large drugmakers.